EMERGENCY MEDICINE CLINICS OF NORTH AMERICA

Emerg Med Clin N Am
20 (2002) 995–1013

Subject Index to Volume 20

Volume 20

February	PEDIATRIC EMERGENCY MEDICINE: CURRENT CONCEPTS AND CONTROVERSIES, pages 1–253
May	BIOTERRORISM, pages 255–535
August	STROKE, pages 537–737
November	ADVANCES IN PREHOSPITAL CARE, pages 739–1013

Note: Page numbers of article titles are in **boldface** type

A

Abdominal emergencies, in children, **139–153**
general approach in, 139–140

Acetaminophen, 204–205
elimination of, 242
overdose of, in child, 241–244

N-Acetylcysteine, in acetaminophen overdose, 243

Acne, neonatal, 29

Activated charcoal, in pediatric poisonings, 232–233

Advanced cardiac life support (ACLS), and chain of survival, efficacy issues for, 762–766
assessment of outcomes in, 760–761
cost considerations and, 761–762
defibrillation in, 761–762, 763–764
early CPR in, 762–763
endotracheal intubation and, 764
pharmacologic interventions in, 764–766
prehospital, **759–770**

Advanced life support, chain of survival in, 7–8
guidelines for, current, 7–8
development of, 6–7
state of, 1–5

Advanced Trauma Life Support, for diagnosis of multiple trauma victims, 353
secondary survey, expansion of, 356–362
traditional survey, expansion of, 356

Airway, management of, advances in, **845–859**
in intracerebral hemorrhage, 641–643
in pediatric resuscitation, 10–12
protection of, in stroke, 690
unprotected, adverse consequences of ventilation with, 846–848

Albuterol, in acute asthma, 124–125

Alphaviruses, 982
clinical presentation of, 317–318
diagnostic testing in, 318
treatment of, 318

American Heart Association, pediatric resuscitation guidelines of, 6–7

Amicar, in von Willebrand disease, 193–194

Aminophylline, in acute asthma, 131

Amiodarone, for pediatric resuscitation, 15–16

Amphetamines, and stroke, 660

Amrinone, in calcium channel blocker overdose, 241

Analgesia, definition of, 201
sedation and, pediatric, contemporary trends in, **199–222**

Analgesics, nonopioid, 204–205

Anemia, autoimmune hemolytic, 184
differential diagnosis of, 179
iron deficiency in, 178–190
pathology of, 179
pediatric hemogram in, 177–178
sickle cell. See *Sickle cell anemia*.

0733-8627/02/$ - see front matter © 2002, Elsevier Science (USA). All rights reserved.
PII: S0733-8627(02)00062-7

Anesthetics, local, 207–209
topical, 208

Anthrax, 978–980
bioterrorism-related inhalational, 280, 281
clinical presentation of, 278
cutaneous, 278–279
diagnosis of, 280–282
endemic inhalational, 279–280
gastrointestinal, 279
history and significance of, 274–278
in children, diagnosis and treatment of, 379–380
in pregnancy, treatment of, 372
infection control precautions and, 282–283
terrorism involving, 332
treatment and prophylaxis of, 283–284

Anthrax Vaccine Adsorbed, 283–284

Antibiotic therapy, for children, in bacterial agents of bioterrorism, 386
in bacterial agents of terrorism in pregnancy, 371–372, 373–374

Antibiotics, appropriate use of, for common infections, increasing resistance and, **69–91**
in children, 72
parental pressure and, 72–73
in bronchiolitis, 99
overprescribing of, 72
prophylactic, to reduced infection, 187
resistance to, history of, 70–73
resistance to bacterial pathogens, 62–63

Anticholinergic agents, in acute asthma, 128–129

Anticoagulation, in stroke, 620–621, 680, 688

Antimicrobials, bioterrorism defense research and, 518–519
biowarfare agents and, 512
history of, 70
in pregnancy, risk categories of, 369

Antiphospholipid antibody syndrome, as cause of stroke, 658–659

Antiterrorism, federal programs and, 482–485

Apnea, in newborn, 38–39

Appendicitis, clinical presentation of, 140–141
diagnostic studies in, 141–142
differential diagnosis of, 142
incidence of, 140
management of, 142

Arena viruses, 376–377

Arterial dissection, stroke in, 659–660

Arteritis, as cause of stroke, 659

Aspirin, 204
in stroke, 619–620, 680, 686
in transient ischemic attack, 602

Asthma, acute exacerbations of, clinical scores in, 120
definition of, 116
disposition from emergency department following, 133–134
history taking in, 117
management of, goals of, 117, 118–119
outpatient treatment following, 134
physical examination in, 117–120, 122–123
pulmonary function tests in, 120–121
pulse oximetry in, 124
treatment of, 124–132
triggers for, 116
pediatric, emergency department management of, **115–138**
problem statement on, 115–116

Aum Shinrikyo, contamination of Tokyo subway system by, 262

B

Bacillus anthracis. See *Anthrax*.

Bacteremia, occult, in febrile children, 56–63
antibiotics in, 61–62
parental values and, 60–61
pneumococcal vaccine in, 63
rapid identification of, new techniques for, 59–60

Bacteria, infectious, as biologic weapons, 978–981

Bag-valve-mask ventilation, 845–846
alternatives to, 850–855
tidal volume for, 848–850

Barbiturates, 212–213

Benzodiazepines, 213

Beta-2-agonists, systemic, in acute asthma, 131

Beta-agonists, inhaled, in acute asthma, 124–128, 130, 134–135

Biologic agent(s), critical, Centers for Disease Control and Prevention 1997 study and, 265
identification of, in biologic agent-caused syndromes, 331
of terrorism, 264

Biologic agent-caused syndromes, 360
biologic agent identification in, 331
diagnostic analyses of, **331–350**
emergency physicians and clinical laboratory communication in, 331–332
exposure to, without warning, 397
pathologic consequences in, 397
pediatric considerations in, 379–383
range of manifestations of, 360
recognition and initial management of, 352

Biologic attack, identification of, 504–510
medical and health communities and, 256
public health response to, Centers for Disease Control and Prevention and, 351–352, 354–355
risk of, 256

Biologic warfare, and terrorism, global trends and effects on global politics, 262
history and threat of, **255–271**
National Intelligence Council and, 262
technologic edge of United States and, 262–263
threat of, 262–263
offensive, traditional agents of, 263

Biologic warfare agents, 256
Biological Weapons Convention (1972) and, 260
during World War II, 258–259
early examples of, 256–257
pre-World War II era, 257–258

Biologic weapons, and chemical weapons of mass destruction, **977–995**
decontaminataion and personal protective equipment against, 983–984, 985
detection of, 983
Gulf War and, 261–262
history of, 977–978
Soviets and, 260–261
types of, 978–983

Biologic weapons programs, offensive, nations having, 265–266

Biological Weapons Convention (1972), and biologic warfare agents, 260

Biotechnology, potential impact on terrorism, 503–504

Bioterrorism, animal-related, veterinary diagnostic laboratory support for, 345–346
cause of crisis related to, 394
children and, 377–383
antibiotic therapy for bacterial agents of, 386
special vulnerabilities to, 378–379
emotional consequences of, anticipation of event and, 394
federal response to, 485
future challenges in, **501–524**
future defense research in, 516–520
infection control measures following, 405
laboratory diagnostics and identification issues associated with, 509
media response to, planning for, 402–403
medical management of, problems related to, 401–403
mental health effects of, 394
primary and secondary emergency prevention and, 394–396
mental health response to, planning for, 403–405
neuropsychiatric syndromes in, 398–399, 400
prevention of, 504
psychosocial casualties of, 393
public information plans for, 402
state and federal response to, **477–499**
surveillance system issues and, 505–507
suspected incident of, environmental sampling in, 345
sample collection in, 346–347
suspected victim of, medical management of, **351–364**
therapeutic interventions in, 399–401
threats in, CDC category A gents in, **273–309**
CDC category B and C gents in, **311–329**
traumatic stress response to, 396–397
vulnerable populations in setting of, **365–392**

Bioterrorism agent(s), bacterial, in pregnancy, antibiotic therapy in, 371–372, 373–374
exposure to, in elderly immunocompromised patients, 383

Bioterrorism agent(s) (*continued*)
identification of, laboratory
component of, 333–336
rapid, importance of, 348–349
technical components of, 346–348
immune response to, in cancer treatment, 385
in organ transplantation, 385
medical sample collection of, 340–343
potential, clinical and laboratory characteristics of, 337–339

Bioterrorism event(s), biologic attack in,
risk to emergency physicians in, 404
risk to primary care physicians in, 404
community activation for, 462
community preparation for, **457–476**
community recovery following, 469
community response to, 462
containment in, 463
data mining and, 460–462
education of healthcare professionals and, 512–516
emergency department and hospital preparedness for, **437–455**
emergency management of mental health in, **393–407**
emergency response to, 462–463
environmental detection of, 507–509
environmental surveillance and, 458–459
epidemiologic surveillance and, 459
federal response to, 487–494
health consequences of, management of, 465–468
healthcare system preparedness issues and, 512–516
healthcare system response planning for, 470–471
large-scale, mass casualty management of, **409–436**
legislative activity following, 516
management plan for, 442–453
activation and notification in, 442–443
alternative care sites in, 446–448
command and control in, 451
coordination and communication in, 451–453
decontamination in, 445–446
expansion of services in, 446–448
facility protection in, 443–445
recovery issues in, 453
staff education and training in, 449–451
supplies and logistics in, 448–449
mass fatality management following, 468
nature of problem, 437–438
potential, features alerting epidemiologists to, 460
pre-clinical diagnostics and, 509–510
prophylaxis, post-exposure measures, and treatments in, 510–512
protection of community personnel and response organizations in, 463–465
public notification of, 468
rehabilitative services following, 469–470
response operations in, management of, 468–469
surveillance and event discovery of, 458
syndromic surveillance and, 459

Bleeding, child presenting with, 191–196
gastrointestinal, in newborn, 35

Blood pressure elevation, preoperative, hemorrhage and, 958–959

Bone marrow transplantation, and stroke, 661

Botulinum toxins, 982–983

Botulism, clinical presentation of, 302–303
diagnosis of, 304
during pregnancy, clinical features of, 374–375
treatment of, 375
history and significance of, 301–302
in children, clinical manifestations of, 381
treatment of, 381–383
infection control precautions in, 304
treatment and prophylaxis of, 304–305

Brain, computed tomography of, analysis of, 555–564, 568–576
assessment of symmetry in, 573–575
location of hemorrhage in, 564–571, 570–573
to examine parenchymal changes, 574, 575

Breast engorgement, in newborn, 29

Breathing, in pediatric resuscitation, 10–12

Bronchiolitis, 93–103
clinical presentation of, 95–96
diagnosis of, 96–97
epidemiology and etiology of, 94–95
outcome of, 102
prevention of, 101–102
respiratory distress in, 95–96
treatment of, 97–101

Bronchodilators, in bronchiolitis, 97–98

Brucellosis, 980
clinical presentation of, 314–315
diagnostic testing in, 315
infection control precautions in, 315
treatment and prophylaxis of, 315–316

Budesonide, in croup, 109

Bupivacaine, 208

Bystander resuscitation, in cardiopulmonary arrest, 8–9

C

Calcium channel antagonists, as toxin in child, 238–241
types of, 239

Cancer, treatment of, immune response to agents of bioterrorism in, 385
smallpox vaccination during, 385–386

Cardiac arrest, sudden, prehospital, outcomes after, 761
versus circulatory arrest, defining of, 964

Cardiac support, advanced. See *Advanced cardiac life support (ACLS)*.

Cardiopulmonary arrest, bystander resuscitation in, 8–9
pediatric, incidence and etiology of, 2–3
survival following, 3–4
factors associated with, 4–5
postarrest stabilization following, 16–17

Cardiopulmonary resuscitation, active compression-decompression, 776–778
and interposed abdominal counterpulsation, 775–776
blood flow during, mechanisms of, 772–774
early, in advanced cardiac life support, 762–763
impedance threshold valve and, 779–781
mechanical devices for, **771–784**
mechanical piston devices for, 778
methods of, in pediatric resuscitation, 12
phased thoracoabdominal compression-decompression in, 781–782
with circumferential vest, 774–775

Cardiovascular care, emergency, automated external defibrillators and, 816–817

Carotid ultrasonography, in transient ischemic attack, 600

Catheter sites, infected, management of, 187–188

Centers for Disease Control and Prevention, 1997 study of, 269
and public health response to biologic attack, 351–352, 354–355
category A agents, **273–309**
category B agents, 311, 313–323
category C agents, 311–312, 323–328
critical biologic agents and, 265
list of "Critical Biological Agents" of, 273–274

Cerebellar infarcts, computed tomography to assess, 579

Cerebral amyloid angiopathy, intracerebral hemorrhage in, 633–634

Cerebral edema, increased, after stroke, treatment of, 692–693

Cerebral infarcts, computed tomography to assess, 579

Chemical asphyxiants, as chemical warfare agents, 991–992

Chemical warfare agents, and biologic weapons of mass destruction, **977–995**
characteristics of, 987
history of, 984
types of, 985–994

Chest radiography, in acute asthma, 132–133

Child(ren), abdominal emergencies in, **139–153**
anthrax in, diagnosis and treatment of, 379–380
appropriate use of antibiotics in, 72–73
bioterrorism and, 377–383
antibiotic therapy for bacterial agents of, 386
special vulnerabilities to, 378–379
botulism in, clinical manifestations of, 381
treatment of, 381–383
considerations in, in biologic agent-caused syndromes, 379–383
death of, coping following resuscitation efforts, 17–18
deceased, caring for family of, 18–20
infants and, fever in, management of, **49–67**
plague in, diagnosis and treatment of, 380–381
respiratory infections in, new approaches to, **93–114**

Child(ren), abdominal (*continued*)
smallpox in, manifestations of, 381
stroke in, **669–683**
younger than 6 years, causes of death in, 224

Child abuse, emergency management in, 45

Chloracetophenon, 993–994

Chloral hydrate, 212

Chlorine, 992

Cidofovir, in smallpox, 288

Ciprofloxacin, in anthrax, 284
in botulism in children, 382

Circulation, management of, in pediatric resuscitation, 12–14

Circulatory arrest, trauma-associated, 964
versus cardiac arrest, defining of, 964

Circumcision, complications of, 31

Clonidine, as toxin in child, 235–237

Clopidogrel, in transient ischemic attack, 603

Clostridium botulinum. See *Botulism*.

CN, 993–994

Coagulopathies, as cause of stroke, 657–658
stroke in children in, 673–674, 679

Cocaine, stroke induced by, 660

Codeine, 206

Colic, by newborn, 45, 46

Combitube®, 850
in management of difficult airway, 854–855
placement of, 851

Community, preparation of, for bioterrorism events, **457–476**, 515–516

Computed tomography, advanced, in acute stroke care, 716–717
background of, 566, 567–568
emergent, for evaluation of stroke, **553–584**
for evaluation of intracerebral hemorrhage, 639–641
in headache evaluation, 562–565
of brain, analysis of, 555–564, 568–576
assessment of symmetry in, 573–575
emergent scan, in acute ischemic stroke, 614–615
location of hemorrhage in, 564–571, 570–573
to examine parenchymal changes, 574, 575
of head, interpretation of, 566–576
scanning in, 554, 567
of skull, in trauma, 576
to assess ischemic patterns of stroke, 575, 576–579
to assess lacunar, cerebral, and cerebellar infarcts, 579, 580
to study stroke, indications for, 557–559

Comstipation, in newborn, 33–34

Congestive heart failure, in newborn, 40

Conjunctivitis, in newborn, 30

Consciousness, altered level of, in newborn, 41–44

Corticosteroids, in croup, 107–109
systemic, in acute asthma, 128, 135

Coumadin therapy, intracerebral hemorrhage associated with, 635

Coxiella burnetti. See *Q fever*.

"Cradle cap," 29

Croup, clinical presentation of, 103–104
diagnosis of, 104
differential diagnosis of, 104–105
etiology and epidemiology of, 103
treatment of, 105–109

Crying, by newborn, 45–46

Cryptosporidium parvum, in bioterrorism, 322

CS, 993–994

Culture, in microbiology laboratory, 347

Cyanide, 991–992

Cytokines, bioterrorism defense research and, 517–518

D

Dark Winter exercises (2001), 268

Death, causes of, in children younger than 6 years, 224

Decontamination, following bioterrorism event, 465, 511–512

Deep venous thrombosis, in stroke, prevention of, 690–691

Defibrillation, biphasic shocks, superior efficacy of, 796–797

early, principle of, 810–811
external, biphasic waveform for, 797–798
hypotheses and electrophysiologic mechanisms of, 789–791
in advanced cardiac life support, 761–762, 763–764
public access, **809–825**
coordination with emergency medical support systems, 820
deployment strategies, 819
incidence and location of cardiac arrest and, 819–820
Phase 1 trial, 820–821
trials and outcomes of, **817–819**
use by rescuers, 819
rectilinear biphasic waveform for, 798–799
transthoracic, historical development of, 786–787
new concepts in, **785–807**
virtual electrode polarization and, 791–796

Defibrillator, automated external, in pediatric resuscitation, 13–14

Defibrillators, automated external, definition of, 811
emergency cardiovascular care and, 816–817
function and usability of, 812
future issues for, 815
in-hospital use of, 817
in public access defibrillation, 809–810
out-of-hospital BLS providers and, 816–817
waveforms of, 812–815

Delirium, as consequence of bioterrorism, treatment of, 399–400

Department of Health and Human Services, 479, 482, 483, 490

Dexamethasone, in croup, 107, 108, 109

Diaper rash, candidal, 30

Diarrhea, in newborn, 34–35

Diphosgene, 992–993

Dipyridamole, extended-release, and aspirin, in transient ischemic attack, 603–604

Disseminated intravascular coagulation, thrombocytopenia in, 190–191

DPT, 211–212

E

Ebola, 300, 376

Educating Health Care Professional(s), continual reassessment and intervention by, 358
decontamination by, 359
diagnosis, treament, and epidemic control by, 359
expansion of secondary survey by, 356–362
expansion of traditional primary survey by, 356
issuance of appropriate warnings by, 362
prevention of spread of disease by, 362
prompt recognition of bioterrorism agents by, 357–359
protection of, in investigation of agents of bioterrorism, 358–359
provision of therapy by, 361

Electrocardiogram, prehospital 12-lead, diagnostic programs, **827–843**
equipment for, and cost effectiveness of, 829–830
feasibility of implementing, 829
implementing effective program for, 838, 839, 840
improved interpretation of, 833
potential benefits of, 830–833
present and future applications of, 833–836, 837

Electrochemiluminescence assays, 348

Emergency department, and hospital, preparedness of, for bioterrorism events, **437–455**

Emergency Management Assistance Compact, 486

Emergency Management Strategic Healthcare Group, 484

Emergency medical dispatch (EMD), **861–877**
background of, 862–863
Criteria-Based Dispatch system and, 864–865
dispatch systems and, 864
dispatch training for, 863
future of, 871–872
information provided to dispatcher, 869
medical control in, 867
medical/legal risk and, 872–873
medical priority dispatch system and, 865–866

Emergency medical (*continued*)
prearrival instructions for, 866–867
predictive strength of local dispatch protocols and, 870–871
referral systems and, 872
role of emergency medical dispatcher in, 863
telephone-assisted cardiopulmonary resuscitation and, 868
training goals, 863–864
warning lights and siren for, 867–868

Emergency medical services (EMS),
abandonment by, 906–908
acute stroke evaluation by, 881–883
advance directives and, 909
Agenda for the Future, 739, 740, 752–754
alerting of stroke team by, 548–550
algorithms of, and prehospital care in major trauma, 955–956
American experience with, 917
and initial stabilization, in stroke, 546–548
and patient care issues, in stroke, 543–546
background of, 739–740
beneficence in, performance threats to, 902–905
clinical care and, 750
communications systems, 749–750
design for stroke management, 883–884
dispatch of, 541–542
education and training for, in stroke, 542–543
education systems, 746–747
endotracheal intubation by, 902–904
equipment of, 947
essential ethics for, **889–913**
European influence on, 916–917
evaluation of, 751–752
first responders of, 923–924
four areas of, in stroke, 543
future of, agenda for, **739–757**
vision for, 740–742
future role in stroke management, 886
historical perspective on, 916–917
history taking by, in stroke, 543–544
hospital phase of, trauma centers and, 924–925
human resources and, 745
impairment and, 905
in prehospital care of stroke patient, 537–538, 541
information systems, 750–751
informed consent/informed refusal for, 908
injury and illness prevention and, 748
legislation and regulation of, 743–744
medical assessment by, 948
medical direction of, 746
operational issues in, **915–929**
paramedic and emergency medical technician, targeting resources of, 924
paramedic experience in, strategies for increasing, 921
paramedic supervisors in, 924
patient preferences, EMTALA and, 909
performance of, ethical breaches in, 901–902
principle-based ethical challenges in, 901
physician mentors for, 926–927
priority medical dispatch of, 922–923
privacy threats to, 908–909
public access to, 748–749
public education about, 747–748
research by, 740
and waiver of consent, 908
respect for patient autonomy, 905
rural systems, 925–926
safe driving in, 904
scene safety and, 947
scene termination and, 910
scope of practice of, 904–905
system finance, 744–745
system of, components of, 918–920
design issues and, 917–926
target response versus uniform response by, 920–921
teamwork in, barriers to, 891–892
ethics of, 890–891
theoretic concerns/premises of, 893–894
triage and resource allocation by, 910
versus tactical emergancy medical support (TEMS), 946–949
virtue-based ethics in, 892–893
virtues in: communication, 899
virtues in: compassion, 897–898
virtues in: confirmation, 900–901
virtues in: empathy, 899
virtues in: justice, 895–896
virtues in: nonjudgment, 896
virtues in: prudence, 895
virtues in: resilence, 898–899
virtues in: self-disclosure, 900
virtues in: self-effacement/charity, 896–897
virtues in: shared power and control, 899
virtues in: trustworthiness, 898

Emergency medical support, tactical. See *Tactical emergency medical support (TEMS)*.

Emergency physicians, and clinical laboratory communication, in biologic agent-caused syndromes, 331–332
in diagnosis of stroke, 554–557
risk to, following biologic attack, 404

Emergency practitioners, future role of, in acute stroke care, 723–725

EMLA, 208

Encephalitides, viral, 982

Encephalitis, tick-borne, 325
West Nile virus, 332

Encephalomyelitis, eastern and western equine, 317–318
Venezuelan, 317–318

Encephalopathies, mimicking stroke, 592

Endotracheal intubation, advanced cardiac life support and, 764
by emergency medical services, 902–904
during pediatric resuscitation, 10–11

Epidemic curves, 413

Epinephrine, high-dose, for pediatric resuscitation, 14–15
racemic, in croup, 105–107

Epsilon poisoning, from *Clostridium perfringens*, 320

Erythrocytopenia, transient, of childhood, 184–185

Escherichia coli, in bioterrorism, 321–323

Esophageal detector device, in tracheal tube placement, 11

Ethics, issues of, and informed consent, in treatment of acute stroke, **701–713**

Ethyl chloride, 208–209

Etomidate, 211

Exercises, weapons of mass destruction readiness, 267–268

Extracorporeal membrane oxygenation, in bronchiolitis, 101

Eyes, exposure to toxins, management of, 233

F

Factor IX deficiency, 196

Factor VIII deficiency. See *Hemophilia* A.

Federal Bureau of Investigation, 488, 489

Federal Emergency Management Agency, 479, 482, 483, 488–489

Fentanyl, 206

Fetal smallpox, 367

Fetal vaccinia, 370

Fever, in children, in occult bacteremia. See *Bacteremia, occult, in febrile children.*
in occult urinary tract infection, 55–56
in infants, and in children, management of, **49–67**
bacterial disease in, 50
chest radiographs in, 53–54
low-risk, screening for, 51–53
older, and in toddlers, 54–55
preliminary reseaarsh in, 51
younger than 1 month of age, 54
in newborn, 35–37

Fever phobia, 63–64

Filoviruses, 376

Fluid resuscitation, in uncontrolled hemorrhage, 961–962
preoperative, complications of, 962–964

Flumazenil, 215

Fluori-methane, 208–209

Fogging effect, 579

Food-borne pathogens, 321–323

Francisella tularensis. See *Tularemia*.

G

Gastroesophageal reflux disease, 144

Gastrointestinal bleeding, in newborn, 35

Gastrointestinal complaints, in newborn, 31–35

Gene amplification assays, 347

Glanders, clinical presentation of, 316
diagnostic testing in, 316–317
infection control precautions in, 317
treatment and prophylaxis of, 317

Glucagon, in calcium channel blocker overdose, 240

Glucocorticoids, in bronchiolitis, 98–99

Glucose-6-phosphate dehydrogenase deficiency, 183

Gulf War, and biologic agents, 261–262

H

Haemophilus influenzae, type B, bacteremia associated with, 58–59

Hantaviruses, 324–325

Head, computed tomography of, interpretation of, 566–576
scanning in, 554, 567

Head and neck, and skin, of newborn, complaints concerning, 28–30

Head injury, blunt, prehospital care in, 967–969
closed, in children, disposition in, 164–165
epidemiology of, 162
evaluation of, 163–164
presentation of, 162–163

Headaches, evaluation of, computed tomography in, 562–565
in children, classification of, 165–166
epidemiology of, 165
evaluation of, 167–168
presentation of, 168
therapy of, 168

Health community, biologic attack and, 256
communication in, in preparation for bioterrorist attack, 516

Health services, integration of, 742

Healthcare services, capacity of, methods to increase, 467
system preparedness issues of, bioterrorism attack and, 512–516

Healthcare system, 741

Heart disease, congenital, 39–41
categories of, 39
differential diagnosis of, 39–40
management of, 41
radiographic findings in, 40–41
stroke in children in, 676

Heliox, in acute asthma, 132
in bronchiolitis, 100

Hematologic emergencies, in pediatric emergency room, **177–198**

Hemiparesis, functional, as stroke mimic, 592

Hemodialysis, to eliminate toxins, 234–235

Hemogram, pediatric, in anemia, 177–178

Hemolytic anemia, autoimmune, 184

Hemolytic uremic syndrome, and thrombocytopenia, 190

Hemophilia A, bleeding in, 195
incidence of, 194
inhibitors in, 195–196
treatment of, 194

Hemophilia B, 196

Hemorrhage, cerebral, location of, computed tomography for, 564–571, 570–573
following blunt versus penetrating trauma, management of, 959–961
intracerebral, **631–654**
airway management in, 641–643
anticoagulation reversal in, 646–647
blood pressure management in, 643–644
clinical presentation of, 637–639
computed tomography for evaluation of, 639–641
definition of, 631
epidemiology of, 631–632
fluid management in, 645–646
increased, management of, 644–645
management of, 641–647
pathophysiology of, 636–637
prevention of, 648
prognosis in, 637
risk factors for, 632–636
seizure prevention in, 646
surgical intervention in, 637–648
post-traumatic, prehospital care in, 956–964
preoperative blood pressure elevation and, 958–959
uncontrolled, fluid resuscitation in, 961–962

Hemorrhagic conversion, after stroke, treatment of, 693, 694

Hemorrhagic fevers, viral, 982
clinical presentation of, 298–300
diagnosis of, 300
history and significance of, 298, 299
infection control precautions in, 300
treatment and prophylaxis of, 301

Hirschsprung disease, 34

HIV, and stroke, 660–661

Homocystinuria, stroke in children with, 679

Hospital(s), diaster planning in, assessment of risks, capabilities, and capacity in, 440–442

basic axioms of, 438–439
emergency department and, preparedness of, for bioterrorism events, **437–455**
preparedness of, for chemical or biologic attack, 513–515

Humidification, in croup, 105

Hyperventilation, in pediatric resuscitation, 17

Hypocholesterolemia, intracerebral hemorrhage in, 634

Hypoglycemia, as stroke mimic, 590–591

Hypothermia, in acute stroke care, 722

I

Ibuprofen, 204

Immunoassays, 347

Immunocompromised patients, elderly, bioterrorism agent exposure in, 383
monkeypox in, 384
Q fever in, 385, 386–387
smallpox in, 384
tularemia in, 385

Immunomodulators, bioterrorism defense research and, 519–520

Infant(s), and children, fever in, management of, **49–67**

Infections, control of, measures for, following bioterrorism event, 405
systemic, mental status changes in, 562

Infectious disease organisms, associated with terrorism, 263

Infectious Disease Society of America, clinical microbiology laboratories and, 332–333

Informed consent, and ethics issues, in treatment of acute stroke, **701–713**
for thrombolytic therapy in stroke, 707–710

Inguinal hernia, incarcerated, clinical presentation of, 149
diagnostic studies in, 149–150
differential diagnosis of, 150
incidence of, 149
management of, 150

Insulin, and glucose, in calcium channel blocker overdose, 240–241

Intensive care unit, admission to, following stroke, 685

Intra-aortic balloon pump, in calcium channel blocker overdose, 241

Intracranial mass lesions, as stroke mimic, 591

Intracranial pressure, increased, after stroke, treatment of, 691–692

Intraosseous access, in pediatric resuscitation, 12–13

Intussusception, clinical presentation of, 145
diagnostic studies in, 145
differential diagnosis of, 146
intestinal obstruction in, 144–145
management of, 146

Iontophoresis, 209

Ipratropium, in acute asthma, 128–129

J

Jaundice, in neonate, 28–29

Joint Commission on Accreditation of Healthcare Organizations, standards of, 439–440

K

Ketamine, 214–215

Ketorolac, 204

L

Laboratory(ies), clinical, challenges of terrorism to, 332
close contact with, on patient status, 344–345
emergency physicians and, communication of, in biologic agent-caused syndromes, 331–332
time for notification of, of suspicion of bioterrorism, 336–344
clinical microbiology, Infectious Disease Society of America and, 332–333
diagnostic, veterinary, support for animal-related bioterrorism, 345–346
diagnostics and identification issues in, related to bioterrorism, 509
in identification of bioterrorism agents, 333–336
of Laboratory Response Network, functions and biosafety levels of, 334
levels in, 334–336

Laboratory Response Network, 333–336
in diagnosis of illnesses caused by toxins, 336
laboratories of, functions and biosafety levels of, 334
levels in, 334–336

Lacunar infarcts, computed tomography to assess, 579, 580

Laryngeal mask airway, 850
airway by endotracheal tube after, 853–854
contraindications to use of, 852–853
in difficult airway, 851–852
in endotracheal intubation, 11–12
placement of, 851

Laryngotracheobronchitis, acute. See *Croup*.

Laryngotracheomalacia, in newborn, 37

Lassa fever, 299, 376–377

Lethargy, in newborn, 41–42

Leukemia, acute, in thrombocytopenia, 190

Levalbuterol, in acute asthma, 125–128

Lewisite, 990–991

Lidocaine, 207–208

Life support, advanced. See *Advanced life support*.

Live Vaccine Strain, 297–298

Long-QT syndrome, 170–171

M

Mace, 993–994

Magnesium, in acute asthma, 130–131

Magnetic resonance imaging, advanced, in acute stroke care, 717–718
diffusion weighted, in acute stroke care, 717
in transient ischemic attack, 600
perfusion, in acute stroke care, 718

Magnetic resonance spectroscopy, in acute stroke care, 718

Malrotation and midgut volvulus, clinical presentation of, 146–147
diagnostic studies in, 147
differential diagnosis of, 147
management of, 148

Marburg virus, 300

Mass panic, risk factors for, 398

Mechanical ventilation, in acute asthma, 132

Meckel's diverticulum, clinical presentation of, 148
diagnostic studies in, 148
differential diagnosis of, 149
management of, 149

Media, education and preparedness of, for bioterrorism event, 515–516

Medical community, biologic attack and, 256

Mental health, effects of bioterrorism on, 394–396
emergency management of, in bioterrorism events, **393–407**

Mental health response, to bioterrorism, planning for, 403–405

Mental status changes, in systemic infections, 562
metabolic evaluation in, 561–562

Meperidine, 206

Metabolic disorders, in children, stroke in, 674–676

Midazolam, 213–214

Migraine, 166
mimicking stroke, 591–592
stroke as complication of, 658

Milia, of head and neck, in newborn, 29

Military antishock trousers, 956–958

Mongolian spots, 29

Monkeypox, in immunocompromised patients, 384

Morphine, 205

Mouth-to-mouth ventilation, 845–846
tidal volume for, 848–850

Myocardial infarction, acute, base physician diagnostic accuracy for, 832
delays in treatment for, 828
incidence of, 827
management of, as model for stroke, 879–880

Myocardium, dysfunction of, shock-induced, 802–803

N

Naloxone, 215

National Diaster Management System, 491–492

Neonate(s), first 30 days of life of, common complaints in, **27–48**
first few days of life of, emergency room visits during, 27–28

Nerve agents, as chemical warfare agents, 985–989

Neurologic problems, common emergent pediatric, **155–176**

Neuroprotective agents, future of, in acute stroke care, 719–721

Neuropsychiatric syndromes, following bioterrorism, 398–399, 400

Neutropenia, 185–187
and cancer, in child, 185–187
autoimmune, 187–188
congenital cyclic, 188
differential diagnosis of, 186

Nipah virus, 323–324

Nitrous oxide, 209–210

Nutrition, in stroke, 690

O

Opiates, 205

Opioid reversal agents, 215

Opioids, 205–207

Organ transplantation, immune response to agents of bioterrorism in, 385

Otitis media, acute, background of, 73–74
diagnosis of, 74
treatment of, 74–75

Oxycodone, 206–207

Oxygen therapy, in acute asthma, 124
in bronchiolitis, 97

P

Palivizumab, in bronchiolitis, 101–102

Panic, mass, risk factors for, 398

Pediatric emergency medicine, **1–247**

Pediatric resuscitation. See *Resuscitation, pediatric.*

Penicillin, in anthrax, 283
in streptococcal pharyngitis, 79

Pentobarbital, 213

Pharyngitis, streptococcal, background of, 77–78
diagnosis of, 78–79
treatment of, 79

Phosgene, 992

Plague, 980
breastfeeding in, 372
clinical presentation of, 290–291
diagnosis of, 291–292
history and significance of, 289–290
in children, diagnosis and treatment of, 380–381
in pregnancy, clinical features of, 370
treatment of, 371–372
infection control precautions in, 292
treatment and prophylaxis of, 292–294

Plasminogen activator, tissue, intra-arterial, in stroke, 687–688
intravenous, in stroke, 686
recombinant, in emergency stroke therapy, consent for, 703–704
stroke patients appropriate for, 705–707

Pneumatic antishock garment, 956–957
reconsideration of, 957–958

Pneumonia, after stroke, prevention of, 691

Poisoning(s), pediatric, activated charcoal in, 232–233
enhanced elimination in, 230, 234–235
epidemiology of, 223–224
gastric emptying in, 230–232
gastrointestinal decontamination in, 230, 231
history taking in, 226
initial assessment and stabilization in, 224–226
laboratory evaluation in, 228, 230
management of, 224–226
monitoring in, 233–234
physical examination in, 226–228
significant toxins in, 235, 236
whole-bowel irrigation in, 233

Post-exposure prophylaxis, following bioterrorism event, 465–466

Postictal states, as stroke mimic, 591

Postpartum stroke, 660

Potential Injury/Illness Creating Event, 409, 410

Pregnancy, antimicrobials in, risk categories of, 369
bacterial agents of terrorism in, antibiotic therapy in, 371–372, 373–374
smallpox in, 366–369

Pregnancy, antimicrobials in (*continued*)
susceptibility to infections in, 365–366

Primary care physicians, risk to, following biologic attack, 404

Projectile vomiting, 33

Propofol, 210–211

Psychosocial casualties, of bioterrorism, 393

Pulmonary function tests, in acute asthma attacks, 120–121

Pulmonary irritants, as chemical warfare agents, 992–993

Pulse oximetry, in acute asthma attacks, 124

Purpura variolosa (hemorrhagic smallpox). See *Smallpox*.

Pyelonephritis, 79–80

Pyloric stenosis, hypertrophic, clinical presentation of, 143
diagnostic studies in, 143–144
differential diagnosis of, 144
incidence of, 142–143
management of, 144

Q

Q fever, 980–981
clinical presentation of, 313
diagnostic testing in, 314
in immunocompromised patients, 385, 386–387
infection control precautions in, 314
treatment and prophylaxis of, 314

R

Regurgitation, by newborn, 31–32

Respiratory arrest, in children, prognosis following, 4

Respiratory complaints, in newborn, 37–38

Respiratory infections, in children, new approaches to, **93–114**

Respiratory syncytial virus, 94
immune globulin, 101

Resuscitation, pediatric, American Heart Association guidelines for, 6–7
automated external defibrillator in, 13–14
breathing and airway management in, 10–12
bystander(lay-rescuer), 8–9
ceasing of, and coping with death, 17–20
current state of evidence about, 1–2
family member presence at, 9–10
intraosseous access in, 12–13
management of circulation in, 12–14
medications in, 14–16
methods of cardiopulmonary resuscitation in, 12
update on, **1–26**

Ribavirin, in bronchiolitis, 99–100

Ricin poisoning, 318–319

Riot-control agents, as chemical warfare agents, 993–994

Russia, weapons of mass destruction and, 266

S

Salmonella, in bioterrorism, 321–323

Sedation, and analgesia, pediatric, contemporary trends in, **199–222**
definitions of, 200–201
evaluation prior to, 201–203
patient monitoring and equipment for, 203–204
postprocedure evaluation following, 216–217
procedural regimen for, 215–216

Sedatives, 210–215

SEIRV analytic model, 422, 423, 424

Seizures, afebrile, in children, classification of, 157, 158
etiology of, 157–158
evaluation of, 158–159
presentation of, 158
therapy of, 159–160
after stroke, treatment of, 693
as stroke mimic, 591
febrile, in children, 156–157
in children, 155–160
neonatal, 42–44
emergency evaluation of, 43–44
etiology of, 43
treatment of, 44

Sepsis, in newborn, 35–37

Shigella, in bioterrorism, 321–323

Shuang huang lian, in bronchiolitis, 100

Sickle cell anemia, abdominal pain in, 182–183
acute chest syndrome in, 182
bacterial infections in, 181–182

deformed red blood cells in, 180
hand-foot syndrome in, 181
priapism in, 183
stroke in, 182
vaso-occlusive crises in, 181

Sickle cell disease, as cause of stroke, 656–657
stroke in children with, 673, 680

Sinusitis, background of, 75–76
diagnosis of, 76–77
treatment of, 77

Skin, and head and neck, of newborn, complaints concerning, 28–30
exposure to toxins, management of, 233

Skull, computed tomography of, in trauma, 576

Smallpox, 981–982
clinical presentation of, 285–286, 287
diagnosis of, 286–287
fetal, 367
history and significance of, 284–285
in children, manifestations of, 381
in immunocompromised patients, 384
in pregnancy, 366–367
vaccination in, 367–369
infection control precautions and, 287–288
treatment and prophylaxis of, 288–289
vaccination against, during cancer treatment, 385–386

Soviets, and biologic agents, 260–261

Special weapons and tactics (SWAT), development of, 932–933

Spectroscopy, magnetic resonance, in acute stroke care, 718

Spherocytosis, hereditary, 184

Staphylococcal enterotoxin B, 983

Staphylococcus enterotoxin B, food poisoning caused by, 320–321

Status epilepticus, classification of, 160
etiology of, 160
presentation of, 160–161
therapy of, 161–162

Streptomycin, in plague, 292–293
in tularemia, 297

Stress response, traumatic, to bioterrorism, 396–397

Stroke, acute, care in, advanced computed tomography in, 716–717
advanced magnetic resonance imaging in, 717–718
emergency practitioners in, future role of, 723–725
future trends in, **715–727**
hypothermia in, 722
magnetic resonance spectroscopy in, 718
neuroprotective agents in, future of, 719–721
differential diagnosis of, 586
emergency medical services evaluation of, 881–883
imaging in, guidelines for, 565
therapy of, ethics and consent to treat issues in, **701–713**
acute ischemic, **609–630**
anticoagulation in, 620–621, 680
aspirin in, 619–620, 680
assessment in, 611–612
differential diagnosis of, 616
emergent computed tomography scan in, 614–615
epidemiology of, 609–610
glucose control in, 618
hypertension management in, 618–619
hyperthermia control in, 617
initial management in, 611–612
intravenous thrombolytic therapy in. See *Thrombolytic therapy, intravenous.*
oxygen in, 616
pathophysiology of, 610
physical examination in, 612–614
post-treatment considerations in, 626
prehospital management in, 611
"stroke chain of survival" and, 610
swallowing evaluation in, 617
uncommon clinical, 613
airway protection in, 690
amphetamines and, 660
antiphospholipid antibody syndrome in, 658–659
arteritis as cause of, 659
as complication of migraine, 658
aspirin in, 686
bone marrow transplantation and, 661
causes of, 553
chain of recovery from, 881
chameleons, 592–593
Cincinnati Pre-hospital Stroke Scale (CPSS) and, 544–545
classification of, 655, 665
coagulopathies as cause of, 657–658
cocaine-induced, 660

Stroke, acute (*continued*)
complications of, prevention of, 690–691
treatment of, 691–693
CT imaging studies in, in focal neurologic deficits, 559–561
indications for, 557–559
diagnosis of, emergency physicians in, 554–557
emergent CT evaluation of, **553–584**
etiology of, evaluation of, 693–695
evaluation of, 661
fever in, management of, 689–690
HIV and, 660–661
in arterial dissection, 659–660
in children, **669–683**
etiology of, 670–677
evaluation of, 677–679, 681
in coagulopathies, 673–674, 679
in homocystinuria, 679
in vascular anomalies, 671–673
in vasospasm, 676
in venous infarcts, 676–677
incidence and outcomes of, 669–670
pathophysiology of, 671
treatment of, 679–681
with heart disease, 676
with metabolic disorders, 674–676
with sickle cell disease, 673, 680
with vasculitis, 675–676
infarct in, prevention of extension of, 688–689
infrequent causes of, **655–668**
intra-arterial tissue plasminogen activator in, 687–688
intravenous tissue plasminogen activator in, 686
ischemic, mimics of, 547
presenting signs for, 544, 545
ischemic patterns of, computed tomography to assess, 575, 576–579
Los Angeles Pre-hospital Stroke Screen (LAPSS) and, 545–546
management of, 664–666
emergency, current status of, 880–881
emergency medical services system design for, 883–884
future role of emergency medical services in, 886
post-emergency department, **685–700**
prehospital, case presentation of, 879
damage control in, **879–887**
mimics of, **585–595**
background of, 587
from emergency department diagnosis, 589
from initial diagnostic impressions in emergency department, 588, 589
identified following studies failing to show ischemic changes, 590
specific, 590–592
studies of, 587–590
"misclassified," 587
mobilization following, 691
model for, management of acute myocardial infarction as, 879–880
nutrition in, 690
patterns of, 580–582
postpartum, 660
prophylaxis of, secondary, 695–696
rehabilitation following, 696–697
sickle cell as cause of, 656–657
subtypes of, 585
thrombolytic therapy in, informed consent for, 707–710

Stroke patient, acute prehospital management of, 884–886
high-risk, education of, 540–541
identification of, 538–540
inclusion and exclusion criteria for t-PA administration in, 544
prehospital care of, **537–552**
"chain of recovery" in, 538, 539
emergency medical services in, 537–538, 541
guidelines for, 546–548

Stroke scale, Cincinnati prehospital, 882

Stroke unit, admission to, following stroke, 685

"Stuffy nose" syndrome, in newborn, 37

Sufentanil, 206

Sulfonylureas, as toxin in child, 237–238

Sulfur mustard, 989–990

Supraventricular tachycardia, vagal maneuvers for, in children, 14

Surveillance system, to identify potential bioterrorism attack, 505–507

Syncope, autonomic causes of, 169–170
cardiac causes of, 170–171
classification of, 169–171
disposition in, 173
epidemiology of, 168–169
evaluation of, 172

noncardiac causes of, 171
presentation of, 171–172

T

Tactical emergency medical support (TEMS), **931–954**
barricade situations and, 937
decontamination by, 938–939
development of SWAT and, 932–933
entry team, 946
environment of operations of, 947–948
forensic evidence preservation and, 937
goals of, 939–941
growth of, 932–935
hazardous materials and, 936–937
medical assessment by, 948–949
medical threat assessment and, 938, 949–951
military development and use of, 932
national interest in, 933
need for, 935–936
professional support for, 934–935
sensory-deprived and sensory-overload physical examination by, 938
standard emergency medical service versus, 946–949
team for, structure of, 941–944
training programs, 933–934
unique attributes and skills of, 936–939
weapons safety and, 936
zones of care and, 944–946

Terrorism, and biologic warfare, global trends and effects on global politics, 262
National Intelligence Council and, 262
technologic edge of United States and, 262–263
threat of, 262–263
biologic agents of, 264
biologic warfare and, history and threat of, **255–271**
challenges of, to clinical laboratories, 332
current threat of, 502–503
evolution of, 479–480
executive and legislative actions in response to, 480–482
federal response to, 480–485
historical perspective on, 479–480
involving anthrax, 332
of 9-11-2001, federal response to, 494–495
potential impact of biotechnology on, 503–504
versus warfare, 502–503

Terrorist groups, and individuals, 266–267
as religously oriented, 266–267

Terrorists, lone, as unpredictable, 267

Thrombocytopenia, acute leukemia in, 190
differnetial diagnosis of, 188–189
from chemotherapy, 191
hemolytic uremic syndrome and, 190
in disseminated intravascular coagulation, 190–191

Thrombocytopenic purpura, acute childhood, 189–190

Thrombolytic therapy, in acute ischemic stroke, 664–666
in stroke, informed consent for, 707–710
intra-arterial, 624–625
intracerebral hemorrhage associated with, 635
intravenous, 621–626
administration of, 622–624
background of, 621
literature review of, 621–622

Ticlopidine, in transient ischemic attack, 602–603

Tissue plasminogen activator, intra-arterial, in stroke, 687–688
intravenous, in stroke, 686
recombinant, in emergency stroke therapy, consent for, 703–704
stroke patients appropriate for, 705–707

Tokyo subway system, contamination by Aum Shinrikyo, 262

TOPOFF exercises (2000), 268

Toxicologic concerns, pediatric, **223–247**

Toxicologic tests, bedside, 229

Toxins, as biologic weapons, 982–983
associated with terrorism, 263–264, 265
common, and antidotes to, 233–234
in pediatric poisonings, 235, 236

Transient ischemic attacks (TIAs), **597–608**
angioplasty and stenting in, 604
as predictor for stroke, 597
atrial fibrillation and anticoagulation in, 601–604
barriers to treatment of, 605
blood pressure management in, 601
carotid artery surgery in, 604
definition of, 597
differential diagnosis of, 599

Transient ischemic (*continued*)
emergency department disposition in, 605–606
emergency department evaluation in, 599–606
epidemiology of, 598
heparin in, 605
management in, 601
pathophysiology of, 598–599
risk factor modification in, 601

Transthoracic defibrillation. See *Defibrillation, transthoracic.*

Trauma, blunt, versus penetrating, hemorrhage following, management of, 959–961
major, prehospital care in, **955–976**
circulatory arrest and, 964
emergency medical service algorithms and, 955–956
in blunt head injury, 967–969
in post-traumatic hemorrhage, 956–964
on-scene time and, impact of, 965–966
ventilatory techniques in, benefits and risks of, 966
detrimental aspects of, 966–967

Traumatic stress response, to bioterrorism, 396–397

Triage management, conventional, 411
in complex humanitarian emergencies, 429–430
in large-scale bioterrorism event, 409, 410
discovery phase of, 411–412
epidemiologic analysis phase of, 413–416
inclusion and exclusion criteria for, 425–427
mathematical modeling in, 416–417
syndromic surveillance in, 412–413
triage authority in, 417–419
triage categories in, 421–425
triage efficiency in, 425
triage goals in, 419–421
in use of weapons of mass destruction, 428–429
lessons for, learned from large-scale disasters, 427–431
preparation for, in Persian Gulf war, 430–431

Tuberculosis, multidrug-resistant, 325

Tularemia, 981
clinical features of, 375
clinical presentation of, 295–296
diagnosis of, 296–297
history and significance of, 294–295
in immunocompromised patients, 385
infection control precautions in, 297
treatment of, 376
and prophylaxis in, 297–298

U

Umbilicus, complications of, in newborn, 30–31

United States offensive biologic weapons program, 259–260

Urinary tract infections, background of, 79–80
diagnosis of, 80–81, 82
in stroke, 691
occult, in febrile children, 55–56
treatment of, 81–83

V

Vaccines, bioterrorism and, 510–511

Vaccinia, fetal, 370

Variola virus. See *Smallpox.*

Vascular abnormalities, in children, stroke in, 671–673
intracerebral hemorrhage in, 635

Vasculitis, stroke in children in, 675–676

Vasopressin, for pediatric resuscitation, 15

Vasospasm, stroke in children in, 676

Venous infarcts, stroke in children in, 676–677

Ventilation, adverse consequences of, with unprotected airway, 846–848
bag-valve-mask, 845–846
alternatives to, 850–855
tidal volume for, 848–850
mouth-to-mouth, 845–846
tidal volume for, 848–850

Ventricular fibrillation, electrophysiologic considerations in, 787–789
long-duration, biphasic waveforms in, 799–802

Vesicants, as chemical warfare agents, 989–991

Viral hemorrhagic fevers. See *Hemorrhagic fevers, viral.*

Virtual electrode polarization, defibrillation and, 791–796

Viruses, infectious, as biologic weapons, 981–982

Vitamin A, in bronchiolitis, 100

Vomiting, by newborn, 31–33

Von Willebrand disease, 191–194
evaluation and treatment of, 193

W

Waterborne pathogens, 321–323

Weapons of mass destruction, federal preparedness programs and, 482–485
Russia and, 266

Weapons of mass destruction readiness exercises, 267–268

West Nile virus encephalitis, 332

Whole-bowel irrigation, in pediatric poisonings, 233

Wolff-Parkinson-White syndrome, 170

Woolsorters' disease, 279–280

Y

Yellow fever, 325

Yersinia pestis. See Plague.